ASO VISUAL ABSTRACT

ASO Visual Abstract: Short-Term Outcomes Following Breast Cancer Surgery With and Without Neoadjuvant Chemotherapy: A Nationwide Administrative Database Study in Japan

Takaaki Konishi, MD^{1,2} , Michimasa Fujiogi, MD^{2,3}, Ayaka Sato, MD, PhD¹, Nobuaki Michihata, MD, MPH, PhD⁴, Ryosuke Kumazawa, MPharm², Hiroki Matsui, MPH², Kiyohide Fushimi, MD, PhD⁵, Masahiko Tanabe, MD, PhD¹, Yasuyuki Seto, MD, PhD¹, and Hideo Yasunaga, MD, PhD²

¹Department of Breast and Endocrine Surgery, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan; ²Department of Clinical Epidemiology and Health Economics, School of Public Health, The University of Tokyo, Tokyo, Japan; ³Department of Emergency Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA; ⁴Department of Health Services Research, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan; ⁵Department of Health Policy and Informatics, Tokyo Medical and Dental University Graduate School, Tokyo, Japan

The association of neoadjuvant chemotherapy and chemotherapy–surgery interval with complications following breast cancer surgery remains unclear. Matched-pair cohort analyses revealed neoadjuvant chemotherapy

was not associated with complications, regardless of interval. Patients can safely receive perioperative treatment without a lengthened interval (<https://doi.org/10.1245/s10434-021-11272-8>).

DISCLOSURE All authors declare no conflicts of interest.